Review

immunosuppressant ctla4ig (Bristol Myers)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bristol Myers immunosuppressant ctla4ig
Immunosuppressant Ctla4ig, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ctla4ig/ctla4+inhibitor+ipilimumab/us12618031-313-20-23
Average 86 stars, based on 1 article reviews

immunosuppressant ctla4ig - by Bioz Stars, 2026-10

86/100 stars

Images

Produced:

Article Title: Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis
Article Snippet: CTLA4Ig is a genetically engineered fusion protein that consists of a human CTLA4 portion fused to a constant IgG1 region (also known as Abetacept, produced by Bristol-Myers Squib, New York City, N.Y., USA). .. CTLA4Ig is a genetically engineered fusion protein that consists of a human CTLA4 portion fused to a constant IgG1 region (also known as Abetacept, produced by Bristol-Myers Squib, New York City, N.Y., USA). ..

Blocking Assay:

Article Title: Donor MHC-specific IgE augments the T and B cell alloresponse in a CD23-dependent manner.
Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article.

Saline:

Article Title: Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats
Article Snippet: 1 Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, The College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.. 2 Transplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.. 3 Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Concentration Assay:

Image Search Results

a Optical image of NICHE and annotated rendering of NICHE and scanning electron microscopy (SEM) images of the two-layer mesh and nanoporous membrane (representative scan images of 5 independent samples). The longitudinal section of NICHE is representative for clarity. Representative Masson’s trichrome staining of fibrotic capsule around b resin and c PA devices implanted in rats for 6 weeks. d Quantification of fibrotic capsule thickness around medical grade titanium (Ti; n = 5), resin ( n = 5), and PA ( n = 4) devices implanted subQ for 6 weeks in rats, mean ± SD, one-way analysis of variance (ANOVA) *** p < 0.001. e Implant r e activity scores of Ti ( n = 5), resi n ( n = 5), and PA ( n = 4) devices implanted subQ for 6 weeks in rats, mean ± SD, one-way ANOVA, n.s. p = 0.1117. Optical images showing cross sections of f resin and g PA NICHE implanted subQ for 6 weeks. Dashed lines indicate cell reservoir. h Resin and PA roughness quantified using atomic force microscopy ( n = 9 devices per material), mean ± SD, unpaired two-tailed student’s t-test ** p < 0.01. i Contact angle analysis of resin and PA devices ( n = 3 devices per material), mean ± SD, unpaired two-tailed student’s t-test *** p < 0.001. j Resin and PA NICHE cell reservoir tissue sections stained with blood vessel marker B. simplicifolia lectin; vessels in red pointed by black arrow heads. k Vascular density quantification of resin ( n = 1) and PA ( n = 4) cell reservoir tissue from independent NICHE, mean ± SD. l Daily percent in vitro release of CTLA4Ig and IgG from NICHE drug reservoir ( n = 4 devices per drug), mean ± SD. Static glucose stimulated insulin release (GSIR) of rat islets after 5 days of incubation with m CTLA4Ig, n ALS, and o CTLA4Ig + ALS ( n = 4 per condition), mean ± SD, o n e-way ANOVA, * p < 0.05, ** p < 0.001, n.s. p > 0.05 of each condition versus vehicle (0 mg/mL). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats

doi: 10.1038/s41467-022-35629-z

Figure Lengend Snippet: a Optical image of NICHE and annotated rendering of NICHE and scanning electron microscopy (SEM) images of the two-layer mesh and nanoporous membrane (representative scan images of 5 independent samples). The longitudinal section of NICHE is representative for clarity. Representative Masson’s trichrome staining of fibrotic capsule around b resin and c PA devices implanted in rats for 6 weeks. d Quantification of fibrotic capsule thickness around medical grade titanium (Ti; n = 5), resin ( n = 5), and PA ( n = 4) devices implanted subQ for 6 weeks in rats, mean ± SD, one-way analysis of variance (ANOVA) *** p < 0.001. e Implant r e activity scores of Ti ( n = 5), resi n ( n = 5), and PA ( n = 4) devices implanted subQ for 6 weeks in rats, mean ± SD, one-way ANOVA, n.s. p = 0.1117. Optical images showing cross sections of f resin and g PA NICHE implanted subQ for 6 weeks. Dashed lines indicate cell reservoir. h Resin and PA roughness quantified using atomic force microscopy ( n = 9 devices per material), mean ± SD, unpaired two-tailed student’s t-test ** p < 0.01. i Contact angle analysis of resin and PA devices ( n = 3 devices per material), mean ± SD, unpaired two-tailed student’s t-test *** p < 0.001. j Resin and PA NICHE cell reservoir tissue sections stained with blood vessel marker B. simplicifolia lectin; vessels in red pointed by black arrow heads. k Vascular density quantification of resin ( n = 1) and PA ( n = 4) cell reservoir tissue from independent NICHE, mean ± SD. l Daily percent in vitro release of CTLA4Ig and IgG from NICHE drug reservoir ( n = 4 devices per drug), mean ± SD. Static glucose stimulated insulin release (GSIR) of rat islets after 5 days of incubation with m CTLA4Ig, n ALS, and o CTLA4Ig + ALS ( n = 4 per condition), mean ± SD, o n e-way ANOVA, * p < 0.05, ** p < 0.001, n.s. p > 0.05 of each condition versus vehicle (0 mg/mL). Source data are provided as a Source Data file.

Article Snippet: The immunosuppressants used for rat studies were CTLA4Ig (Abatacept, Bristol-Myers Squibb) and rabbit anti-lymphocyte serum (ALS; Accurate chemical); and for NHP studies anti-thymocyte globulin (ATG; Sanofi), CTLA4Ig (Belatacept, Bristol-Myers Squibb), and anti-CD154 [5C8H1] (NIH Nonhuman Primate Reagent Resource, RRID: AB_2716324).

Techniques: Electron Microscopy, Membrane, Staining, Activity Assay, Microscopy, Two Tailed Test, Marker, In Vitro, Incubation

a In vitro tube formation activity of human umbilical vein endothelial cells (HUVEC) in the presence of different drug concentrations (mg/mL). Supplemented media was used as positive inducer (+), 30 µM suramin as positive inhibitor (-), and non-supplemented media as control (Veh). b Total length quantification and c number of segments of tube formation ( n = 4 biological replicates per condition), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001). d qPCR analysis of vascular related genes in HUVEC after treatment with different concentrations of ATG and CTLA4Ig (mg/mL). Gapdh gene was used as internal control and fold-change in gene expression is relative to control untreated cells. ( n = 4 biological replicates), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001; n.s. p > 0.05). e Quantification of VEGF levels in cell reservoir and surrounding microenvironment for control and IS release samples ( n = 4 biological replicates), mea n ± SD, unpaired two-tailed student’s t -test n.s. p > 0.05. f Fluorescence intensity measurements of IHC analysis in g ( n = 4 biological replicates), mean ± SD, unpaired two-tailed student’s t -test n.s. p > 0.05. g Representative sections of NICHE control and IS release slides stained with functional blood vessel markers CD31 (red), VE-cadherin (green), and eNOS (gold). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats

doi: 10.1038/s41467-022-35629-z

Figure Lengend Snippet: a In vitro tube formation activity of human umbilical vein endothelial cells (HUVEC) in the presence of different drug concentrations (mg/mL). Supplemented media was used as positive inducer (+), 30 µM suramin as positive inhibitor (-), and non-supplemented media as control (Veh). b Total length quantification and c number of segments of tube formation ( n = 4 biological replicates per condition), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001). d qPCR analysis of vascular related genes in HUVEC after treatment with different concentrations of ATG and CTLA4Ig (mg/mL). Gapdh gene was used as internal control and fold-change in gene expression is relative to control untreated cells. ( n = 4 biological replicates), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001; n.s. p > 0.05). e Quantification of VEGF levels in cell reservoir and surrounding microenvironment for control and IS release samples ( n = 4 biological replicates), mea n ± SD, unpaired two-tailed student’s t -test n.s. p > 0.05. f Fluorescence intensity measurements of IHC analysis in g ( n = 4 biological replicates), mean ± SD, unpaired two-tailed student’s t -test n.s. p > 0.05. g Representative sections of NICHE control and IS release slides stained with functional blood vessel markers CD31 (red), VE-cadherin (green), and eNOS (gold). Source data are provided as a Source Data file.

Techniques: In Vitro, Activity Assay, Control, Gene Expression, Two Tailed Test, Fluorescence, Staining, Functional Assay

Plasma levels of a ALS and b CTLA4Ig of NICHE ( n = 12 to day 63, n = 8 to day 92, n = 5 to day 112, n = 3 to day 192) and IP ( n = 8 to day 63, n = 5 to day 112) rats, mean ± SD, unpaired two-tailed student’s t -test between NICHE and IP overall average concentrations, (*** p < 0.001). Black triangles indicate drug reservoir reloading. The red triangle indicates systemic ALS bolus. LOQ limit of quantitation. Quantification of immunosuppressants in c peripheral organs and d transplant microenvironment at endpoint of NICHE and IP rats ( n = 8), mea n ± SD, unpaired two-tailed student’s t -test between NICHE and IP rats for each organ (* p < 0.05; ** p < 0.01; *** p < 0.001; n.s. p > 0.05; n.q. = not quantifiable). FC = fibrotic capsule. e Quantification of lymphocytes in blood expressed as fold change to day 0 of NICHE ( n = 8 to day 56, n = 5 to day 115), IP ( n = 5), and rats receiving vehicle ( n = 4). f Quantification of Tregs in blood on day 84 of NICHE, IP, and healthy rats ( n = 5), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001; n.s. p = 0.1643). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats

doi: 10.1038/s41467-022-35629-z

Figure Lengend Snippet: Plasma levels of a ALS and b CTLA4Ig of NICHE ( n = 12 to day 63, n = 8 to day 92, n = 5 to day 112, n = 3 to day 192) and IP ( n = 8 to day 63, n = 5 to day 112) rats, mean ± SD, unpaired two-tailed student’s t -test between NICHE and IP overall average concentrations, (*** p < 0.001). Black triangles indicate drug reservoir reloading. The red triangle indicates systemic ALS bolus. LOQ limit of quantitation. Quantification of immunosuppressants in c peripheral organs and d transplant microenvironment at endpoint of NICHE and IP rats ( n = 8), mea n ± SD, unpaired two-tailed student’s t -test between NICHE and IP rats for each organ (* p < 0.05; ** p < 0.01; *** p < 0.001; n.s. p > 0.05; n.q. = not quantifiable). FC = fibrotic capsule. e Quantification of lymphocytes in blood expressed as fold change to day 0 of NICHE ( n = 8 to day 56, n = 5 to day 115), IP ( n = 5), and rats receiving vehicle ( n = 4). f Quantification of Tregs in blood on day 84 of NICHE, IP, and healthy rats ( n = 5), mean ± SD, one-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001; n.s. p = 0.1643). Source data are provided as a Source Data file.

Techniques: Clinical Proteomics, Two Tailed Test, Quantitation Assay

Review

immunosuppressant ctla4ig (Bristol Myers)

Structured Review

Images

Related Articles

Produced:

Blocking Assay:

Saline:

Concentration Assay:

Similar Products

Image Search Results